反应详情

The title compound (20 mg) was prepared following the general procedure of Example 1 from 2-((4-fluorobenzylamino)methyl)-7,8-dihydro-3H-pyrano[4,3-d]pyrimidin-4(5H)-one (80 mg, 0.28 mmol) and 2-(4-(4-fluorobenzoyl)piperidin-1-yl)acetic acid (86 mg, 0.28 mmol, 85% purity). 1H NMR (400 MHz, CDC3) δ 7.98 (dd, J=8.0, 5.5 Hz, 2H), 7.10-7.35 (m, 4H), 6.90-7.10 (m, 2H), 4.46-4.67 (m, 3.5H), 4.29 (s, 1.5H), 3.78-4.03 (m, 1H), 3.42 (br. s., 3H), 3.05 (t, J=11.5 Hz, 2H), 2.68 (t, J=5.3 Hz, 3H), 2.59 (t, J=5.5 Hz, 1H), 2.38 (br. s., 1H), 2.09-2.31 (m, 3H), 1.88 (br. s., 1H), 1.74-1.86 (m, 1H). HRMS calculated for C29H30F2N4O4 537.2331. found (ESI, [M+H]+), 537.2313. MS m/z 537.2 (M+1), retention time=3.25 min.